Literature DB >> 12522773

Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update.

Malini D Coopamah1, M Bernadette Garvey, John Freedman, John W Semple.   

Abstract

Autoimmune thrombocytopenic purpura (AITP) is a bleeding disorder in which autoantibodies are directed against an individual's own platelets, leading to enhanced clearance through Fc receptor (R)-mediated phagocytosis by macrophages residing in the reticuloendothelial system (RES), particularly in the spleen. The production of IgG autoantibodies is critically dependent on cellular immune mechanisms particularly relating to T cells. We review the recent literature of the cell-mediated immunology of AITP focusing on platelet phenotype, genetics, T-cell reactivities, and cytokine profiles in patients with AITP. Understanding the interaction between these cell-mediated mechanisms is vital for developing antigen specific immunotherapies to treat this autoimmune disease. Copyright 2003, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12522773     DOI: 10.1053/tmrv.2003.50004

Source DB:  PubMed          Journal:  Transfus Med Rev        ISSN: 0887-7963


  21 in total

Review 1.  The ITP syndrome: pathogenic and clinical diversity.

Authors:  Douglas B Cines; James B Bussel; Howard A Liebman; Eline T Luning Prak
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

2.  A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).

Authors:  Philip Young-Ill Choi; Fernando Roncolato; Xavier Badoux; Sundra Ramanathan; Shir-Jing Ho; Beng H Chong
Journal:  Blood       Date:  2015-05-13       Impact factor: 22.113

Review 3.  Childhood immune thrombocytopenia: Clinical presentation and management.

Authors:  Mohamed El Faki Osman
Journal:  Sudan J Paediatr       Date:  2012

Review 4.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

5.  Coronary artery bypass grafting in idiopathic thrombocytopenia: use of thromboelastometry without platelet transfusion.

Authors:  Michele Rossi; Michael Lewis; Nevil Hutchinson
Journal:  Tex Heart Inst J       Date:  2010

6.  Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia.

Authors:  Mattias Olsson; Pierre Bruhns; William A Frazier; Jeffrey V Ravetch; Per-Arne Oldenborg
Journal:  Blood       Date:  2005-01-21       Impact factor: 22.113

7.  Differential Expression of T-bet and GATA3 in Egyptian Children with Idiopathic Thrombocytopenic Purpura.

Authors:  Amira Ahmed Hammam; Dina Ahmed Ezzat; Marwa Hamed Abd Elwahab
Journal:  Indian J Hematol Blood Transfus       Date:  2015-12-11       Impact factor: 0.900

8.  Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP).

Authors:  R M Talaat; A M Elmaghraby; S S Barakat; M El-Shahat
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 9.  Refractory idiopathic immune thrombocytopenic purpura in children: current and future treatment options.

Authors:  Paul Imbach
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Covalent inactivation of factor VIII antibodies from hemophilia A patients by an electrophilic FVIII Analog.

Authors:  Stephanie Planque; Miguel A Escobar; Keri C Smith; Hiroaki Taguchi; Yasuhiro Nishiyama; Elizabeth Donnachie; Kathleen P Pratt; Sudhir Paul
Journal:  J Biol Chem       Date:  2008-03-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.